Literature DB >> 17689706

Right ventricular dysfunction is an independent predictor of survival in patients with dilated chronic Chagas' cardiomyopathy.

Maria do Carmo P Nunes1, Manoel Otávio C Rocha, Antônio Luiz P Ribeiro, Enrico A Colosimo, Renato A Rezende, Guilherme Augusto A Carmo, Marcia M Barbosa.   

Abstract

BACKGROUND: Right ventricular (RV) involvement is a typical feature of Chagas' disease. In patients with congestive heart failure of other etiologies, RV dysfunction is a strong indicator of poor prognosis. However, the prognostic value of RV dysfunction in patients with Chagas' cardiomyopathy has not been reported. This study sought to investigate the prognostic value of RV dysfunction, apart from other well established risk factors, in patients with Chagas' cardiomyopathy.
METHODS: The study enrolled 158 patients (99 men; mean age of 48+/-12 years) from a tertiary center for Chagas' disease. Patients were selected if found to have both the diagnosis of Chagas' disease and cardiomyopathy. All patients underwent a comprehensive Doppler echocardiogram and the global RV function was quantitatively assessed using the RV index of myocardial performance (Tei index).
RESULTS: Most of the patients were in NYHA classes I and II (79%). During a mean follow up of 34+/-23 months, 44 patients (28%) died: 24 (55%) patients died of progressive heart failure and 16 (36%) of sudden death. RV Tei index emerged as an independent predictor of survival (hazard ratio 5.75, 95% confidence interval 1.69 to 19.51). Kaplan-Meier survival curves showed a higher cumulative mortality among patients in the highest quartile of RV Tei index, compared with other 3 quartiles (log-rank statistic 21.87, p<0.001). After adjustment for clinical data and LV ejection fraction, RV Tei index in the highest quartile (>0.56) remained a significant predictor of death (hazard ratio 5.29, 95% confidence interval 2.43 to 11.52).
CONCLUSIONS: RV function assessed by the Tei index added significant prognostic information, incremental to the NYHA clinical classification and to the standard echocardiographic evaluation of LV systolic function. A simple measure of a Doppler index, which allows analysis of both systolic and diastolic function of the RV, appears to be a useful non-invasive tool for risk stratification in patients with dilated chronic Chagas' cardiomyopathy.

Entities:  

Mesh:

Year:  2007        PMID: 17689706     DOI: 10.1016/j.ijcard.2007.06.012

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  18 in total

Review 1.  Right side of heart failure.

Authors:  Maya Guglin; Sameer Verma
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

2.  Echocardiographic parameters and survival in Chagas heart disease with severe systolic dysfunction.

Authors:  Daniela do Carmo Rassi; Marcelo Luiz Campos Vieira; Ana Lúcia Martins Arruda; Viviane Tiemi Hotta; Rogério Gomes Furtado; Danilo Teixeira Rassi; Salvador Rassi
Journal:  Arq Bras Cardiol       Date:  2014-02-10       Impact factor: 2.000

Review 3.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

4.  Altered Cardiomyocyte Function and Trypanosoma cruzi Persistence in Chagas Disease.

Authors:  Jader Santos Cruz; Artur Santos-Miranda; Policarpo Ademar Sales-Junior; Renata Monti-Rocha; Paula Peixoto Campos; Fabiana Simão Machado; Danilo Roman-Campos
Journal:  Am J Trop Med Hyg       Date:  2016-03-14       Impact factor: 2.345

5.  Bone marrow cell therapy ameliorates and reverses chagasic cardiomyopathy in a mouse model.

Authors:  Regina C S Goldenberg; Linda A Jelicks; Fabio S A Fortes; Louis M Weiss; Leonardo L Rocha; Dazhi Zhao; Antonio Campos de Carvalho; David C Spray; Herbert B Tanowitz
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

6.  Molecular imaging, biodistribution and efficacy of mesenchymal bone marrow cell therapy in a mouse model of Chagas disease.

Authors:  Antonio C Campos de Carvalho; David C Spray; Linda A Jelicks; Herbert B Tanowitz; Vera Maria Peters; Rosalia Mendez-Otero
Journal:  Microbes Infect       Date:  2014-09-16       Impact factor: 2.700

Review 7.  Clinical and echocardiographic predictors of mortality in chagasic cardiomyopathy--systematic review.

Authors:  Clodoval de Barros Pereira Júnior; Brivaldo Markman Filho
Journal:  Arq Bras Cardiol       Date:  2014-06-06       Impact factor: 2.000

8.  Mesenchymal bone marrow cell therapy in a mouse model of chagas disease. Where do the cells go?

Authors:  Linda A Jelicks; Wade Koba; Herbert B Tanowitz; Rosalia Mendez-Otero; Antonio C Campos de Carvalho; David C Spray
Journal:  PLoS Negl Trop Dis       Date:  2012-12-13

9.  Alterations to the Cardiac Metabolome Induced by Chronic T. cruzi Infection Relate to the Degree of Cardiac Pathology.

Authors:  Kristyn Hoffman; Zongyuan Liu; Ekram Hossain; Maria Elena Bottazzi; Peter J Hotez; Kathryn M Jones; Laura-Isobel McCall
Journal:  ACS Infect Dis       Date:  2021-04-12       Impact factor: 5.578

10.  Mode of death on Chagas heart disease: comparison with other etiologies. a subanalysis of the REMADHE prospective trial.

Authors:  Silvia M Ayub-Ferreira; Sandrigo Mangini; Victor S Issa; Fátima D Cruz; Fernando Bacal; Guilherme V Guimarães; Paulo R Chizzola; Germano E Conceição-Souza; Fabiana G Marcondes-Braga; Edimar A Bocchi
Journal:  PLoS Negl Trop Dis       Date:  2013-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.